Litcius/Paper detail

CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As “Add-on” to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study

Srđan Verstovšek

202062nd ASH Annual Meeting and Exposition15 citations

Topics & Concepts

RuxolitinibBromodomainMyelofibrosisMedicineCancer researchInternal medicineChemistryBiochemistryGeneBone marrowAcetylationMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsMultiple Myeloma Research and Treatments
CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As “Add-on” to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study | Litcius